GlassScriptPhysician profile
Jeanann Vawter
NPI 1043253776
$97,024.24
in general payments reported to CMS, 2019-2025
28 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15K · 2022: $36K · 2023: $20K · 2024: $15K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $11K · Travel and Lodging: $4,172 · Consulting Fee: $1,688 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,400.00 |
| Food and Beverage | $11,254.78 |
| Travel and Lodging | $4,172.32 |
| Consulting Fee | $1,687.50 |
| Education | $232.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $79,546.60 | 2021-2025 | Erleada, Akeega, Rybrevant |
| Coloplast Corp | $5,235.47 | 2021-2025 | Isiris Astent Removal Device, Altis, Saffron |
| Axonics, INC. | $3,347.19 | 2021-2024 | Axonics |
| Teleflex LLC | $2,266.38 | 2021-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $1,660.87 | 2021-2025 | Lithovue, Axonics, Greenlight Xps |
| Janssen Scientific Affairs, LLC | $1,523.05 | 2021-2025 | Erleada |
| Myriad Genetic Laboratories, INC. | $711.78 | 2021-2024 | Prolaris |
| Agiliti Surgical, INC. | $631.91 | 2024-2025 | Greenlight Xps Laser, Dornier Thulio Laser, Sonablate Hifu |
| Medtronic, INC. | $343.02 | 2022-2023 | Interstim |
| Astellas Pharma US INC | $261.16 | 2021-2025 | |
| Laborie Medical Technologies Corp. | $229.59 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Urogen Pharma, INC. | $177.16 | 2025 | |
| Foundation Medicine, INC. | $144.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $142.96 | 2021 | |
| Novo Nordisk INC | $129.50 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $118.27 | 2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $88.73 | 2023 | Gemtesa |
| Abbvie INC. | $67.59 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $65.84 | 2021 | |
| Dendreon Pharmaceuticals LLC | $65.23 | 2021 | |
| Pfizer INC. | $56.05 | 2021-2024 | |
| Urovant Sciences INC | $47.75 | 2022 | |
| Myovant Sciences INC. | $42.41 | 2021 | |
| Amgen INC. | $33.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.97 | 2021-2022 | |
| Blue Earth Diagnostics | $26.13 | 2021 | |
| Merck Sharp & Dohme LLC | $18.60 | 2021 | |
| Antares Pharma, INC. | $15.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanann Vawter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.